Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Cancer -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (52)	5/13/2001 7:27:28 PM
From: tuck	Read Replies (1) \| Respond to of 1840

Miljenko, Thanks. Comparing CEGE's press release with the abstract, I see it could mislead those not familiar with the trial. Message 15794007 The abstract mentions the total patient size of 80. The PR uses the 30 it says were "evaluable." I would like to see what they mean by that. I'm not expecting much, it's an interim evaluation. As you suggest, best to wait for the full abstracts or finished trial data to be presented. If memory serves, this data comes from about the half-way point of the trial. I'd track it down, but I've got to go cook dinner for my Mom; it'll have to wait. I missed your rationale regarding your dislike of personalized cancer vaccines. Do you have a pointer to a prior post on the subject? Does your reference to anti-VEGF antibody efficacy fluctuations relate to personalized cancer vaccines? A marker? Cheers, Tuck